The Galien Forum USA 2018

PANEL
3

Chair
Michael Rosenblatt, MD
Chief Medical Officer
Flagship Pioneering, Dallas

Panelists
Sir Andrew Dillon
Chief Executive
National Institute for Health
and Care Excellence (NICE), UK

John Furey
Chief Operating Officer
Spark Therapeutics Inc.

Scott Howel, MD, MBA
Vice‐President and Head,
US Market Access
Novartis Pharmaceuticals Inc.

Gary P. Pisano, PhD
Harry E. Figgie Professor
of Business Administration
Harvard Business School

Kent Rogers, MBA
Senior Vice President,
Industry Relations

UnitedHealth Group Inc.

Panel Intro

Making Medicines Affordable


Michael Rosenblatt

Michael Rosenblatt, MD
Chief Medical Officer
Flagship Pioneering, Dallas

Dr. Rosenblatt’s career has been in academia, pharma and biotech/venture. He is a physician–scientist. He now serves as Chief Medical Officer of Flagship Pioneering in Cambridge, MA, a firm that originates new biotech companies. Previously, he was Merck’s first Chief Medical Officer. He also served as Dean of Tufts University School of Medicine, and before that, Robert Ebert Professor of Molecular Medicine and George R. Minot Professor at Harvard Medical School. He served as President of Beth Israel Deaconess Medical Center and Director of the Harvard-MIT Division of Health Sciences and Technology. At Merck, he co-led development of alendronate (FOSAMAX) for osteoporosis.

He received the Fuller Albright Award, the Vincent du Vigneaud Award, and the Chairman’s Award from Merck. Active in biotechnology, he was a founder of ProScript, which discovered bortezomib (Velcade) for multiple myeloma, and Radius, which developed abaloparatide (Tymlos) for osteoporosis. Currently, he is a member of the Harvard Medical School Board of Fellows, and the research advisory committees of Massachusetts General, Brigham and Women’s, and Boston Children’s hospitals. He graduated summa cum laude from Columbia, and received his M.D. magna cum laude from Harvard. Internship, residency, and endocrinology training were all at Massachusetts General Hospital.


Andrew Dillon

Sir Andrew Dillon
Chief Executive
National Institute for Health and Care Excellence (NICE), UK

Andrew Dillon graduated from the University of Manchester in 1975. He has held a number of senior management positions in the UK National Health Service, including General Manager of the Royal Free Hospital and Chief Executive of St George’s Healthcare NHS Trust in London. He joined NICE as its founding Chief Executive in 1999.


John Furey

John Furey
Chief Operating Officer
Spark Therapeutics Inc.

John Furey is responsible for global commercial operations, medical affairs, technology development and technical operations at Spark Therapeutics. He has 25 years of experience in developing and implementing operational strategies and leading commercial and technical teams. Prior to joining Spark Therapeutics, John was senior vice president and head of global operations for Baxalta, where he directed manufacturing, quality, engineering, and process development. He actively managed a $2.5 billion production budget across Baxalta’s global network and led a first-in-class supply chain organization for rare diseases. John led the team that coordinated and delivered the successful establishment of Baxalta through a spin out from Baxter and led the Baxter Vaccine inline business to realize significant top line and bottom line growth.

He also spent two years in China as general manager of Pfizer’s vaccine business unit following a role with responsibility for global pricing and reimbursement at Pfizer Vaccines. In these roles, John gained extensive experience in pipeline development and global product launches. Earlier in his career, he held both commercial and operations positions of increasing scope and responsibility with Pfizer and Wyeth Pharmaceuticals. John has an executive M.B.A. from St. Joseph’s University, Philadelphia, a B.S. from Trinity College, Dublin, and a diploma in Environmental Health from the Dublin Institute of Technology.


Scott Howell

Scott Howell, MD, MBA
Vice‐President and Head,
US Market Access
Novartis Pharmaceuticals Inc.

Scott Howell is Vice President, Market Access (MA) for US Pharmaceuticals at Novartis Pharmaceuticals Corporation, a position he has held since June 2017. Scott leads all areas of MA including Pricing and Contracting, Managed Care, Distribution, and Patient Services. He also serves as a member of the US Pharmaceuticals Executive Committee (PEC). Prior to joining Novartis, Scott served as Vice President of Market Access at Jazz Pharmaceuticals, a rare disease and orphan drug company, where he led a fully integrated pricing, contracting, distribution, reimbursement and managed care department. Previously, he worked for Cardinal Health as Senior Vice President, Clinical Services and spent a number of years at Genentech where he held a variety of leadership positions in the Market Access environment.

Earlier in his career, Scott was Vice President, Pharmacy Affairs at Highmark Blue Cross Blue Shield where he led the pharmacy program. Before Highmark, he held a variety of managed care leadership roles at SmithKline Beecham/GlaxoSmithKline. Scott began his career as a general internist and worked several years in private practice before working in academic medicine at the Ohio State University.

He has been lecturing on health policy and industry strategy for a number of years, primarily in the graduate programs at U.C. Berkeley, and has co-authored and contributed to a number of industry-related papers. Scott earned his undergraduate degree at Notre Dame and his medical degree at Ohio State. He completed his medical internship and residency and also earned an M.B.A at Duke University.


Gary P. Pisano

Gary P. Pisano, PhD
Harry E. Figgie Professor
of Business Administration
Harvard Business School

Gary Pisano is the Harry Figgie Professor of Business Administration at the Harvard Business School where he currently serves as Senior Associate Dean for Faculty Development (promotions and tenure). He joined the Harvard faculty in 1988 after completing a Ph.D. at the University of California Berkeley.

Over the course of his career, Pisano has explored fundamental questions about how organizations innovate, learn, compete, and grow.  His research and consulting experience has spanned a broad range of industries including aerospace, automobiles, apparel, biotechnology and pharmaceuticals, entertainment, financial services, health care, restaurants, semiconductors, software, specialty chemicals, and web services.

He has published over 100 scholarly articles and case studies on such topics as technology and operations strategy, competitive strategy, intellectual property, the management of innovation, organizational learning, commercializing science, business model design and innovation, global competitiveness, and corporate growth.   His article “Dynamic Capabilities and Strategic Management” (with David Teece and Amy Shuen, Strategic Management Journal, 1997) is one of the most highly cited papers in the field of management and was instrumental in launching a new capability-based theory of strategy. His article “Restoring American Competitiveness” (with Willy Shih) won the 2009 McKinsey Award for best publication in the Harvard Business Review. He has written six books, including: The Development Factory; Strategic Operations; Operations, Strategy and Technology; Science Business; and Producing Prosperity. His latest book, Creative Construction: The DNA of Sustained Innovation, examines how larger enterprises can leverage scale to become transformational innovators.

At Harvard, Pisano has taught MBA, executive, and doctoral courses, and has mentored a number of doctoral students. He has created and currently teaches a new MBA electric course “Managing Growth” based on his current research on the drivers and impediments to organizational scaling and growth. He is also the co-creator and co-chair of a new executive program called “Driving Profitable Growth”.

In addition to his academic research and teaching, Pisano serves as an advisor to senior leaders at leading companies around the world and has been a director of both public and private company boards. He currently serves on the board of directors of Axcella Health and Celixir.


Kent Rogers

Kent Rogers, MBA
Senior Vice President,
Industry Relations

UnitedHealth Group Inc.

Kent currently serves as the Senior Vice President, Industry Relations for OptumRx with responsibility for drug formulary management for all books of business on behalf of internal and external clients of United Health Group. Kent also has leadership oversight of the brand/generic procurement teams, BriovaRx Specialty and Infusion contracting operations, the FFS Medicaid team, and the Formulary Consulting Group for OptumRx. OptumRx is the pharmacy benefit management division of Optum servicing over 130 million members and processing 1.4 billion pharmacy claims for over $87 billion in annual drug spend. He has more than 25 years of experience in the healthcare industry, focusing primarily on payer, channel and patient services strategies.

Prior to OptumRx, Kent was a Principal with the Blue Fin Group consulting firm, served as the Vice President of Managed Markets at Acorda Therapeutics – a biotechnology firm focusing on CNS disease states, and held senior leadership positions at Schering Plough and Merck in areas of sales and market access/reimbursement. His career experience includes business development, health economics/outcomes research, building and leading market access teams, developing and implementing payer access and channel strategies, and launching patient services programs. Kent has a Bachelor of Science in Business Management from Indiana University, and an MBA from Emory University’s Goizueta School of Business.